Your session is about to expire
← Back to Search
Cytotoxic T Cells for Lymphoma (ALCI2 Trial)
ALCI2 Trial Summary
This trial is testing whether a new experimental therapy, third party LMP specific cytotoxic T lymphocytes (CTLs), can prevent or treat EBV Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after treatment, including the best treatment.
ALCI2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowALCI2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.ALCI2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV positive.My graft-versus-host disease is more severe than Grade II.My tumor is positive for the Epstein-Barr virus.I am mostly able to care for myself but may need help.I have EBV-related lymphoma or lymphoproliferative disease, in remission or with detectable disease after a stem cell transplant.My kidney function, measured by creatinine, is less than twice the normal level for my age.
- Group 1: LMP1/2 CTLs (Group A)
- Group 2: LMP1/2 CTLs (Group B)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What hazards does Group B LMP1/2 CTLs present for human health?
"Due to the limited data supporting safety and efficacy, our team at Power gave LMP1/2 CTLs (Group B) a score of 1 on a scale from 1 to 3."
Is the recruitment process for this research still ongoing?
"The clinical trial's data hosted on clinicialtrials.gov reveals that it is no longer open to applicants, as the last update was from May 11th 2022. Despite this, there are 1825 other trials actively searching for participants."
Share this study with friends
Copy Link
Messenger